Inhibitors of platelet functions;Medicaments inhibiteurs des fonctions plaquettaires

Sang Thrombose Vaisseaux

Volumn 12, Issue SPEC. ISS., 2000, Pages 3-11

  Lecompte, T ^a   Ferrari, E ^a   Nguyen, P ^a   De Moerloose, P ^a   Samama, C M ^a  

^a UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ASASANTINE; CARDIOSOLUPSAN; CLOPIDOGREL; DIPYRIDAMOLE; EPTIFIBATIDE; FLURBIPROFEN; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; HEPARIN; LAMIFIBAN; LYSINE ACETYLSALICYLATE; TICLOPIDINE; TIROFIBAN; UNCLASSIFIED DRUG; WARFARIN;

ANGINA PECTORIS; ANTICOAGULANT THERAPY; BLEEDING; CEREBROVASCULAR ACCIDENT; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG INDICATION; DRUG MECHANISM; HEART INFARCTION; HEMOSTASIS; HEPARINIZATION; HUMAN; HYPERTENSION; INTERNATIONAL STANDARD UNIT; NEUTROPENIA; PHARMACODYNAMICS; REVIEW; THROMBOCYTE AGGREGATION INHIBITION; THROMBOSIS;

EID: 0033647227     PISSN: 09997385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Platelet-active drugs: The relationships among dose, effectiveness, and optimal therapeutic range
2. Platelet glycoprotein IIb/IIIa receptor antagonists in cardiovascular disease
3. CAST: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke
4. The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneaous heparin, both, or neither among 19,435 patients with acute ischaemic stroke
5. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial
6. Extra-cranial bleeding and other symptoms due to low dose aspirin and low intensity oral anticoagulation
7. Thrombosis Prevention Trial: Randomised trial of low intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischemic heart disease in men at increased risk
8. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation
9. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischemic events
10. European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke
11. A clinical trial comparing three antithrombotic-drug after coronary-artery stenting
12. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents
13. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting
14. Low-dose and high dose acetylsalicylic acid for patients undergoing carotid endarterectomy: A randomised controlled trial
15. Clopidogrel: A novel antiplatelet and antithrombotic agent
16. The P2Y1 receptor, necessary but not sufficient to support full ADP-induced platelet aggregation, is not the target of the drug clopidogrel
17. Dipyridamole inhibits platelet aggregation in whole blood
18. Clinical pharmacology of platelet cyclooxygenase inhibition
19. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin
20. Optimal dose for starting and maintaining low dose aspirin
21. Aspirin therapy: Optimized platelet inhibition with different loading and maintenance doses
22. Acute myocardial infarction: Pre-hospital and in-hospital management
23. Aspirin
24. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2
25. ISIS-3: A randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction
26. The duration of pretreatment with ticlopidine prior to stenting is associated with the risk of procedure-related non-Q-wave myocardial infarctions
27. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty
28. Platelet GPIIb-IIIa blockers
29. Platelet glycoprotein IIb/IIIa antagonists. What are the relevant issues concerning their pharmacology and clinical use?
30. Platelet anti-aggregating activity and tolerance of clopidogrel in atherosclerotic patients
31. Medicaments antiplaquettaires (inhibiteurs des fonctions plaquettaires)
32. Allongement du temps de saignement et traitement anti-agregant plaquettaire
33. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 on the activated clotting time
34. In vitro effects of the platelet glycoprotein IIb/IIIa receptor antagonist c7E3 Fab on the activated clotting time
35. Effets hematologiques indesirables de la ticlopidine
36. Thrombotic thrombocytopenic purpura related to ticlopidine
37. Thrombotic thrombocytopenic purpura associated with ticlopidine: A review of 60 cases
38. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
39. Platelet glycoprotein IIb/IIIa receptor blockade with abciximab and low-dose heparin during percutaneous coronary revascularization
40. Sustained suppression of ischemic complications of coronary intervention by platelet GPIIb/IIIa blockade with abciximab - One-year outcome in the EPILOG trial
41. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
42. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors
43. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study
44. Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease
45. Antithrombotic therapy in patients undergoing coronary angioplasty
46. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators: Observations in animals and humans
47. Abciximab facilitates the rate and extent of thrombolysis. Results of the Thrombolysis In Myocardial Infarction (TIMI) 14 trial
48. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction
49. United Kingdom transient ischemic attack (UK-TIA) aspirin trial: Interim results
50. A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after transient ischemic attack or minor ischemic stroke
51. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
52. Collaborative overview of randomised trials of antiplatelet therapy. II: Maintenance of vascular graft or arterial patency by antiplatelet therapy
53. The case for low-dose aspirin for the prevention of myocardial infarction: But how low is low?
54. The gastrointestinal toxicity of aspirin: An overview of randomized controlled trials
55. Antithrombotic and thrombolytic therapy for ischemic stroke
56. Meeting highlights. Highlights of the 48th scientific sessions of the American College of Cardiology
57. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation
58. Safety and efficacy of ticlopidine for only 2 weeks after successful intracoronary stent placement
59. Collaborative overview of randomised trials of antiplatelet therapy. III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients
60. Indications et contre-indications des transfusions de plaquettes
61. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high risk patients
62. Effects of profound platelet inhibition with c7E3 Fab before coronary angioplasty on complications of coronary bypass surgery
63. Pharmacologic and transfusion strategies to alter function and production: c7E3 (Abciximab)
64. ReoPro removal during cardiopulmonary bypass using a hemoconcentrator
65. Anticoagulants and spinal-epidural anesthesia
66. CLASP: A randomised trial of low-dose aspirin for the prevention and treatment of preeclampsia among 9,364 pregnant women
67. Preoperative antiplatelet therapy does not increase the risk of spinal hematoma associated with regional anesthesia
68. A comparison of the effects of aspirin on bleeding time measured using the Simplate-TM method and closure time measured using the PFA-100-TM, in healthy volunteers
69. Acute profound thrombocytopenia following c7E3 Fab (abciximab) therapy: Case reports, review of the literature and implications for therapy
70. Occurence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization
71. Correspondence. Acute profound thrombocytopenia after c7E3 Fab therapy
72. Thrombopenie sous abciximab dans le traitement des syndromes coronariens aigus par angioplastie
73. Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The Platelet glycoprotein IIb/IIIa in Unstable angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial experience
74. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GPIIb/IIIa therapy
75. Rapid platelet-function assay. An automated and quantitative cartridge-based method
76. Bleeding complications with the chimeric antibody to platelet glycoprotein IIb/IIIa integrin in patients undergoing percutaneous coronary intervention
77. Modifiable risk factors for vascular access site complications in the IMPACT II trial of angioplasty with versus without eptifibatide
78. Monitoring the effect of heparin bolus during percutaneous coronary angioplasty (PTCA): Assessment of three bedside coagulation monitors
79. Use of antithrombotic agents during pregnancy